Clobazam

CHEMBL70418 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

300.7 g/mol

LogP

2.1

Phase

4

A benzodiazepine anticonvulsant that enhances the inhibitory neurotransmitter GABA to reduce seizure frequency, approved as an add-on therapy for Lennox-Gastaut syndrome. It also has anxiolytic properties and is used in some countries for short-term anxiety relief.

الوزن الجزيئي

300,7400 g/mol

LogP

2,10

TPSA

40,60 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pain Management Asthma Epilepsy Schizophrenia Generalized Anxiety Disorder Insomnia Hypertension Chronic Pain Heart Failure

آلية العمل

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21

InChI

InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3

Molecular Formula

C16H13ClN2O2

HBD / HBA

- / 2

الروابط القابلة للدوران

1

الذرات الثقيلة

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A benzodiazepine anticonvulsant that enhances the inhibitory neurotransmitter GABA to reduce seizure frequency, approved as an add-on therapy for Lennox-Gastaut syndrome. It also has anxiolytic properties and is used in some countries for short-term anxiety relief.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Clobazam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL70418. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2789. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Clobazam على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C16H13ClN2O2
المرادفات: 2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.